ImmuCell Corporation (ICCC) Stock Price & Analysis
ImmuCell Corporation (ICCC) — MoonshotScore 82/100 (Exceptional band), calculated Nov 22, 2026. Price $10.92 (-2.41%), as of the Nov 20, 2026 trading session; market cap $99.3M.
Educational signal · not a buy or sell recommendation · How to read this
ImmuCell Corporation · ICCC · NASDAQ
ImmuCell Corporation focuses on developing, manufacturing, and marketing animal health products for the dairy and beef cattle industries. Their primary product, First Defense, is an orally administered scours preventive for newborn calves.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · ImmuCell (ICCC)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 4 of the last 5 reports
- Altman Z 4.89 · Piotroski F 8
- ROE 6.0% · ROA 7.5% · current ratio 4.61
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 82 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional |
The score was 82 in the stored Nov 21, 2026 snapshot and remains 82 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.92 | |
| Change on the day | -2.41% | |
| Market capitalisation | $99.3M | — |
| Price / earnings (trailing) | 54.60 | |
| Shares traded on the day | 18.7K |
Price & events
Other perspectives
Council score for ImmuCell (ICCC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is ImmuCell (ICCC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ImmuCell Corporation (ICCC) is listed on NASDAQ. It employs 73 people. The market values it at $99.3M.
What do the latest results show for ImmuCell (ICCC)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of the last 5 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $6M | -$139,748 | -$0.02 (diluted) |
| Q4 FY2025 | $8M | -$3M | -$0.31 (diluted) |
| Q1 FY2026 | $10M | $2M | $0.21 (diluted) |
| Q2 FY2026 | $7M | $2M | $0.20 (diluted) |
What are the financial strengths and risks for ImmuCell (ICCC)?
Short answer · as of
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 4.89 · Piotroski F 8. Trailing ratios: ROE 6.0% · ROA 7.5% · current ratio 4.61.
How does ImmuCell compare with its peers?
Short answer
ImmuCell's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| ImmuCell (ICCC) — this page | $10.92 | $99.3M | 82 |
| $15.47 Nov 20, 2026 | $83.3M | 82 5-pillar Nov 22, 2026 | |
| $3.57 Nov 20, 2026 | $155M | 72 5-pillar Nov 22, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 70 5-pillar Nov 22, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 22, 2026 | |
| $133.72 Nov 20, 2026 | $330B | 68 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 64 5-pillar Nov 22, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 22, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ICCC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ICCC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ImmuCell (ICCC)?
Investor Questions: ICCC Stock
These answers are editorial: 1 of these 9 answers is drawn from the ICCC research dossier (written May 8, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ICCC?
ICCC carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. ImmuCell Corporation focuses on developing, manufacturing, and marketing animal health products for the dairy and beef cattle industries.
Is ICCC a good stock to buy?
Stock Expert AI does not rate ICCC buy, sell or hold. ImmuCell Corporation carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ICCC stock price today?
The last price recorded for ImmuCell Corporation (ICCC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about ICCC stock?
Analyst coverage of ImmuCell Corporation (ICCC) is limited, reflecting its small-cap status. Key valuation metrics to consider include the company's market capitalization relative to its revenue and earnings potential.
What are the key factors to evaluate for ICCC?
ImmuCell Corporation (ICCC) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Focus on preventative animal health solutions aligns with the increasing demand for proactive veterinary care. Not financial advice.
How frequently does ICCC data refresh on this page?
ICCC's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ICCC's recent stock price performance?
ImmuCell Corporation (ICCC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in dairy and beef cattle health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ICCC overvalued or undervalued right now?
The trailing P/E of ImmuCell Corporation (ICCC) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ICCC?
Fractional-share availability for ImmuCell Corporation (ICCC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 8, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 7 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com